Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Liu, H. Dai, L. Liang, L. Peng, J. Jiang (Beijing, China). Elevation of serum tumor markers in patients with interstitial lung disease. Eur Respir J 2011; 38: Suppl. 55, 4776

Member's Comments

No comment yet.

Related content which might interest you: Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007 Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002 KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Usefulness of serum bird specific antibody levels in patients with interstitial pneumonia Source: International Congress 2016 – Orphan diseases II Year: 2016 Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Tumor markers in bronchial secretions and serum in patients with lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Increased cytokeratin-19 expression in fibrotic interstitial lung disease Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020 Year: 2020 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 A clinicopathological review of interstitial pneumonia with marked IgG4 positive plasma cells infiltration Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Increased serum α1-antitrypsin level in COPD patients with predominant lung emphysema Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001 Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009 Circulating fibrocytes in interstitial lung disease Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Elevation of serum napsin A levels in patients with hypersensitive pneumonia Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Serum heat shock protein 47 levels in patients with drug induced lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013